Skip to content

Study · Systematic review · 2026

9 results

Clinical evidence of semaglutide for metabolic dysfunction-associated steatotic liver disease (MASLD): An updated meta-analysis.

Peng TR, Lin HH, Tseng TL, Wu TW, Chao YC

British journal of clinical pharmacology11 Jun 2026Cited by 2 (Europe PMC)

PMID42273973 (opens in a new tab)PMCIDPMC13420891 (opens in a new tab)DOI10.1002/bcp.70629 (opens in a new tab)PepBankPUB-42273973
Source linkPubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a meta-analysis of semaglutide in MASH, semaglutide significantly improved MASH resolution without worsening fibrosis (OR 3.48).

    In plain wordsIn a pooled analysis of trials, semaglutide made fatty liver inflammation resolve more often than control treatment.

    Peptide
    Semaglutide
    Outcome
    IncreaseMASH resolution without worsening of fibrosis
    Study

    n: not reported in source

    Comparator
    Control
    Analysis
    Primary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Measurements

    OR
    3.48 ratio
    MASH resolution

    Source sentences

    Summary
    Semaglutide significantly improved MASH resolution without worsening fibrosis (OR 3.48; 95% CI: 2.68-4.53; p < .00001).
    1 context sentence
    Summary · context
    Ten studies (n = 1908) were analysed.
  2. 02HumanSystematic reviewEfficacy outcome

    In a meta-analysis of semaglutide in MASH, pooled fibrosis improvement of at least 1 stage was not statistically significant (OR 1.17).

    In plain wordsIn a pooled analysis of trials, semaglutide did not clearly improve liver scarring compared with control treatment.

    Peptide
    Semaglutide
    Outcome
    No significant changeFibrosis improvement of at least 1 stage
    Study

    n: not reported in source

    Comparator
    Control
    Analysis
    Primary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Measurements

    OR
    1.17 ratio
    fibrosis improvement

    Source sentences

    Summary
    However, pooled fibrosis improvement (≥1 stage) was not statistically significant (OR 1.17; 95% CI: 0.49-2.80; p = .72).
    1 context sentence
    Summary · context
    Ten studies (n = 1908) were analysed.
  3. 03HumanSystematic reviewEfficacy outcome

    In a meta-analysis of semaglutide in MASH, semaglutide reduced liver stiffness (mean difference -1.25 kPa).

    In plain wordsIn a pooled analysis of trials, semaglutide lowered liver stiffness compared with control treatment.

    Peptide
    Semaglutide
    Outcome
    DecreaseLiver stiffness
    Study

    n: not reported in source

    Comparator
    Control
    Analysis
    Secondary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Measurements

    MD
    −1.25 kPa
    liver stiffness

    Source sentences

    Summary
    Radiologically, semaglutide reduced liver stiffness (MD -1.25 kPa; 95% CI: -2.18 to -0.32; p = .009) and increased relative liver fat reduction of ≥30% (OR 7.16; 95% CI: 3.08-16.64; p < .00001).
    1 context sentence
    Summary · context
    Ten studies (n = 1908) were analysed.
  4. 04HumanSystematic reviewEfficacy outcome

    In a meta-analysis of semaglutide in MASH, semaglutide significantly reduced AST.

    In plain wordsIn a pooled analysis of trials, semaglutide lowered the liver enzyme AST compared with control treatment.

    Peptide
    Semaglutide
    Outcome
    DecreaseAST
    Study

    n: not reported in source

    Comparator
    Control
    Analysis
    Secondary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Significant reductions in AST, ALT and cholesterol were also observed.
    1 context sentence
    Summary · context
    Ten studies (n = 1908) were analysed.
  5. 05HumanSystematic reviewEfficacy outcome

    In a meta-analysis of semaglutide in MASH, semaglutide significantly reduced ALT.

    In plain wordsIn a pooled analysis of trials, semaglutide lowered the liver enzyme ALT compared with control treatment.

    Peptide
    Semaglutide
    Outcome
    DecreaseALT
    Study

    n: not reported in source

    Comparator
    Control
    Analysis
    Secondary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Significant reductions in AST, ALT and cholesterol were also observed.
    1 context sentence
    Summary · context
    Ten studies (n = 1908) were analysed.
  6. 06HumanSystematic reviewEfficacy outcome

    In a meta-analysis of semaglutide in MASH, semaglutide significantly reduced cholesterol.

    In plain wordsIn a pooled analysis of trials, semaglutide lowered cholesterol compared with control treatment.

    Peptide
    Semaglutide
    Outcome
    DecreaseCholesterol
    Study

    n: not reported in source

    Comparator
    Control
    Analysis
    Secondary
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Significant reductions in AST, ALT and cholesterol were also observed.
    1 context sentence
    Summary · context
    Ten studies (n = 1908) were analysed.
  7. 07HumanSystematic reviewEfficacy outcome

    In a meta-analysis of semaglutide in MASH, semaglutide increased the chance of a relative liver fat reduction of at least 30% (OR 7.16).

    In plain wordsIn a pooled analysis of trials, semaglutide made a large liver fat reduction much more likely than control treatment.

    Peptide
    Semaglutide
    Outcome
    IncreaseRelative liver fat reduction of at least 30%
    Study

    n: not reported in source

    Comparator
    Control
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Measurements

    OR
    7.16 ratio
    liver fat reduction >=30%

    Source sentences

    Summary
    Radiologically, semaglutide reduced liver stiffness (MD -1.25 kPa; 95% CI: -2.18 to -0.32; p = .009) and increased relative liver fat reduction of ≥30% (OR 7.16; 95% CI: 3.08-16.64; p < .00001).
    1 context sentence
    Summary · context
    Ten studies (n = 1908) were analysed.
  8. 08HumanSystematic reviewSafety outcome

    In a meta-analysis of semaglutide in MASH, semaglutide carried a higher risk of gastrointestinal adverse events than control (RR 1.83).

    In plain wordsIn a pooled analysis of trials, semaglutide was linked to more stomach and gut side effects than control treatment.

    Peptide
    Semaglutide
    Outcome
    IncreaseGastrointestinal adverse events
    Study

    n: not reported in source

    Comparator
    Control
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    RR
    1.83 ratio
    gastrointestinal adverse events

    Source sentences

    Summary
    Regarding safety, semaglutide was associated with a higher risk of gastrointestinal-related adverse events (RR = 1.83; 95% CI: 1.20-2.79) compared with the control group, but no significant difference was observed in the risk of serious adverse events (RR = 1.07; 95% CI: 0.82-1.39).
    1 context sentence
    Summary · context
    Ten studies (n = 1908) were analysed.
  9. 09HumanSystematic reviewSafety outcome

    In a meta-analysis of semaglutide in MASH, the risk of serious adverse events did not differ significantly from control (RR 1.07).

    In plain wordsIn a pooled analysis of trials, semaglutide did not cause significantly more serious side effects than control treatment.

    Peptide
    Semaglutide
    Outcome
    No significant changeSerious adverse events
    Study

    n: not reported in source

    Comparator
    Control
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Measurements

    RR
    1.07 ratio
    serious adverse events

    Source sentences

    Summary
    Regarding safety, semaglutide was associated with a higher risk of gastrointestinal-related adverse events (RR = 1.83; 95% CI: 1.20-2.79) compared with the control group, but no significant difference was observed in the risk of serious adverse events (RR = 1.07; 95% CI: 0.82-1.39).
    1 context sentence
    Summary · context
    Ten studies (n = 1908) were analysed.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.